iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Get Free Report) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totaling 108,461 shares, a growth of 382.5% from the June 15th total of 22,477 shares. Currently, 1.9% of the shares of the stock are short sold. Based on an average daily volume of 77,170 shares, the short-interest ratio is currently 1.4 days.
Hedge Funds Weigh In On iShares Genomics Immunology and Healthcare ETF
An institutional investor recently raised its stake in iShares Genomics Immunology and Healthcare ETF stock. Ameriprise Financial Inc. raised its holdings in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Free Report) by 8.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 71,473 shares of the company’s stock after acquiring an additional 5,540 shares during the period. Ameriprise Financial Inc. owned approximately 1.42% of iShares Genomics Immunology and Healthcare ETF worth $1,688,000 at the end of the most recent reporting period.
iShares Genomics Immunology and Healthcare ETF Trading Down 2.8%
Shares of iShares Genomics Immunology and Healthcare ETF stock traded down $0.95 during trading on Friday, hitting $33.55. The stock had a trading volume of 55,587 shares, compared to its average volume of 44,156. iShares Genomics Immunology and Healthcare ETF has a 12 month low of $20.93 and a 12 month high of $34.97. The firm has a market cap of $194.59 million, a price-to-earnings ratio of 14.76 and a beta of 0.92. The business’s 50-day moving average is $30.71 and its 200 day moving average is $29.59.
About iShares Genomics Immunology and Healthcare ETF
The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.
Featured Stories
- Five stocks we like better than iShares Genomics Immunology and Healthcare ETF
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for iShares Genomics Immunology and Healthcare ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Genomics Immunology and Healthcare ETF and related companies with MarketBeat.com's FREE daily email newsletter.
